Patent Quality

Patent quality is a multidimensional concept — it encompasses legal correctness, claim clarity, and the degree to which the patent represents a genuine advance over the prior art: DIMENSIONS OF PATENT QUALITY: (a) PRIOR ART CORRECTNESS: does the patent claim subject matter that is genuinely novel (§ 102) and non-obvious (§ 103) over the prior art? A patent that was allowed only because the examiner missed prior art is a low-quality patent; (b) CLAIM CLARITY: are the claims clear enough that a person of ordinary skill in the art can determine whether a given product or process infringes? Vague claims (e.g., using undefined terms with unclear scope) impose costs by creating uncertainty about infringement exposure; (c) WRITTEN DESCRIPTION AND ENABLEMENT: does the specification adequately support the claimed scope? A patent that claims broadly but only describes narrowly may fail written description or enablement requirements; (d) PROCEDURAL CORRECTNESS: were all required disclosures made? Did the applicant disclose the best mode? Were all inventors identified? WHO CARES ABOUT PATENT QUALITY: (a) DEFENDANTS: low-quality patents that never should have issued are used to extract settlements from companies that didn't infringe or where the claims were not novel; (b) LICENSEES: companies signing patent licenses want to ensure the licensed patents are valid and enforceable; (c) PATENT BUYERS: investors and acquirers of patent portfolios pay premium prices for patents that would survive validity challenges; (d) PATENT OWNERS: owning many low-quality patents creates enforcement costs with minimal return; a smaller portfolio of high-quality patents may be more valuable; (e) SOCIETY: low-quality patents impose a tax on innovation by creating exclusionary rights over technology that should be in the public domain.

The USPTO has implemented multiple initiatives over the years to improve examination quality: ENHANCED PATENT QUALITY INITIATIVE (EPQI, 2015): broad quality initiative covering: (a) examiner training improvements; (b) supervisor review programs; (c) clarity standards for claim language; (d) pre-examination interview programs; (e) after final consideration pilot 2.0 (AFCP 2.0); CLARITY OF THE RECORD PILOT (2018): encouraged examiners to create a clearer record during examination; explicit examiner statements of what was searched, what was found, and why the claims were allowed; more useful for later litigation and IPR proceedings; INTERVIEW PRACTICE IMPROVEMENTS: pre-examination interviews (applicants can discuss the application with the examiner before the first office action); after final interviews; telephonic interviews to resolve issues efficiently; EXAMINATION QUALITY DASHBOARDS: USPTO publishes examination quality data including: compliance rates (percentage of office actions that meet quality standards); allowance rates by technology area and examiner; examiner agreement rates with supervisor reviews; PRIOR ART DATABASES: USPTO has expanded access to non-patent literature databases including technical journals, foreign patent databases, and product manuals; examiner training on international prior art search; PRE-ISSUANCE SUBMISSIONS: AIA established pre-issuance submissions (§ 122(e)): third parties can submit prior art before the patent issues; submission must be made before a first rejection or 6 months after publication, whichever is later; allows competitors to introduce prior art the examiner may have missed; SUBJECT MATTER ELIGIBILITY GUIDANCE: Alice Corp. v. CLS Bank created massive uncertainty for software patents; USPTO has issued multiple rounds of guidance (2019 Revised Guidance, subsequent examples) to help examiners apply § 101 consistently; APPEALS AND QUALITY: applicants who believe examination was flawed can appeal to the PTAB; PTAB reversal rates are an indirect metric of examination quality.

Continuation practice is one of the most contested aspects of patent quality debate: WHAT CONTINUATIONS DO: continuation applications claim the benefit of an earlier application's filing date while presenting new claims; applicants can file continuations indefinitely as long as there is a pending parent; QUALITY CONCERNS FROM CONTINUATIONS: (a) CLAIM REFINEMENT BASED ON COMPETITOR PRODUCTS: applicants can watch competitors enter the market and then draft continuation claims to specifically cover the competitor's products; this 'hindsight claiming' allows applicants to claim subject matter they observed rather than invented; (b) SUBMARINE PATENTS: historically (under the old 17-years-from-issue system), continuations could result in patents that issued decades after the original filing, surprising companies that had built businesses in the technology space; current 20-years-from-filing term limits the underwater period; (c) PORTFOLIO INFLATION: companies can accumulate large numbers of continuation patents that all claim priority to a single provisional or nonprovisional application; 100+ patents in a single family is not unusual for major technology companies; each continuation requires prosecution resources and examiner time; THE CONTINUATION DEBATE: defenders argue continuations are legitimate tools for: refining claim scope as technology evolves; pursuing different aspects of an invention in separate applications; maintaining prosecution pending pending while developing the market; critics argue continuations enable: extending effective patent terms; gaming the system to capture competitor technology; inflating patent counts without genuine innovation; EMPIRICAL DATA: studies by Lemley and others show that continuation families account for a disproportionate share of patent litigation; continuation claims are more likely to be asserted in litigation than original claims.

Patent quality is difficult to measure directly — instead researchers use proxy metrics: PROXY METRICS FOR PATENT QUALITY: (a) FORWARD CITATION COUNT: how many subsequent patents cite this patent? Highly cited patents may indicate more foundational or important inventions; but citation count can be inflated by applicants citing their own prior art; (b) IPR INSTITUTION RATE: what percentage of IPR petitions challenging similar patents are instituted by the PTAB? A high institution rate for a technology class suggests many patents in that class have prior art issues; (c) CLAIM SURVIVAL RATE IN IPR: what percentage of challenged claims survive IPR? Cancelled claims indicate prior art missed by the original examiner; (d) ALLOWANCE RATE BY EXAMINER: examiners with very high allowance rates may be less rigorously applying the prior art standard; allowance rates by technology center are published by the USPTO; (e) MAINTENANCE FEE PAYMENT RATES: patent holders pay maintenance fees (due at 3.5, 7.5, and 11.5 years); if maintenance fees are not paid, the patent lapses; patents not worth maintaining reveal that the market valued them at zero; (f) LITIGATION OUTCOMES: what percentage of patents that go to trial are found invalid? Higher invalidity rates = lower quality; PUBLIC DATA SOURCES: USPTO PEDS (Patent Examination Data System): allows analysis of examination outcomes by art unit, examiner, and technology class; Patent Center (formerly EFS-Web): file wrapper access; IPR/PGR statistics: PTAB posts quarterly statistics on institution rates and claim survival rates; Google Patents: citation data and prosecution history; WRITERSIDE COMMERCIAL: Derwent Innovation, PatSeer, Cipher: advanced analytics on patent quality metrics.

Patent quality is a central determinant of patent value — both in licensing negotiations and in M&A or portfolio transactions: QUALITY IN LICENSING: (a) VALIDITY RISK DISCOUNT: a licensee's first question is whether the patent is valid; if the licensee's attorney identifies prior art that wasn't before the examiner, the licensee has leverage to negotiate a lower royalty rate; low-quality patents get significant discounts (or refusals to license); (b) CLAIM COVERAGE: a patent that covers exactly what the licensee's product does has licensing power; a patent that covers an outdated approach the licensee doesn't use has no leverage; (c) PROSECUTION HISTORY ESTOPPEL: patents with heavily amended claims have narrowed scope and limited doctrine of equivalents; this reduces coverage and licensing leverage; (d) ALICE/§ 101 RISK: patents on software or business methods face invalidity risk under Alice; sophisticated licensees will challenge § 101 eligibility before paying; (e) IPPR THREAT: if the licensee believes the patent is invalid, they can file an IPR petition (within 1 year of being served with suit) to invalidate the patent; a valid, well-prosecuted patent has much higher licensing value because the licensor can credibly threaten litigation; QUALITY IN M&A AND PORTFOLIO TRANSACTIONS: buyers pay per-patent premiums for: strong forward citation history; clean prosecution history (few amendments, broad surviving claims); no known prior art threats; coverage of commercially significant products; conversely, portfolios with many patents that wouldn't survive IPR or Alice challenges trade at discounts; due diligence on patent quality is a significant component of IP M&A; QUALITY AND PAE STRATEGY: PAEs prefer lower-quality patents in some respects: patents with enough ambiguity in claim scope to create uncertainty; but not so invalid as to be killed in IPR; the sweet spot for a PAE is a patent with uncertain validity that costs more to litigate than to settle.